Eledon Pharmaceuticals, Inc. Share Price & Technical Analysis
ELDN · $3.58 (+4.99%)
Healthcare / Biotechnology
$3.58
+4.99%
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD…
Price chart
Seasonality
Jun has 0 positive and 5 negative years (last 5 years shown)
-5% return in Jun, -16% avg return in past 3 year Jun month.
88% return in 2026, 32% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 38% | 18% | 19% | 16% | 3% | -5% | – | – | – | – | – | – | 88% |
| 25 | 7% | -7% | -19% | -3% | -6% | -10% | 19% | -16% | 0% | 65% | -64% | -6% | -40% |
| 24 | 0% | 0% | 17% | 14% | 17% | -4% | 7% | -3% | -11% | 88% | -2% | -13% | 110% |
| 23 | 50% | -27% | 4% | -12% | 0% | -33% | 0% | 7% | -7% | 7% | -27% | 64% | 25% |
| 22 | -7% | -15% | 3% | -22% | 7% | -25% | 25% | 23% | -26% | -14% | -4% | -4% | -61% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Neutral
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$274.02M
P/E ratio
—
52W high
$4.60
52W low
$1.35
Volume
18,25,220
Beta
0.97
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹36,480
Abbott Laboratories Cede…
₹34,460
Eli Lilly And Company Ce…
₹30,560
Unitedhealth Group Inc C…
₹18,330
Elevance Health Inc
₹7,255
Frequently asked questions
- What is Eledon Pharmaceuticals, Inc. share price today?
- Eledon Pharmaceuticals, Inc. (ELDN) last traded around $3.58 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ELDN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ELDN. Download the app for real-time alerts.
- How can I analyze Eledon Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.